The Innovative Medicines Initiative has now launched IMI2 – Call 13 with the following topics:
- Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches
- Genome-environment interactions in inflammatory skin disease
- The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
- Mitochondrial dysfunction in neurodegeneration
- Support and coordination action for the projects in the neurodegeneration area of the Innovative Medicines Initiative
- A sustainable European induced pluripotent stem cell platform
- Linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice
- Human tumour microenvironment immunoprofiling
- Conception – Continuum of evidence from pregnancy exposures, reproductive toxicology and breastfeeding to improve outcomes now
- Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system
- Translational safety biomarker pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
- Pilot programme on a clinical compound bank for repurposing – this programme contains four topics on cardiovascular diseases and diabetes; respiratory diseases; neurodegenerative diseases; and rare/orphan diseases
Deadline for submitting short proposals: 28 February 2018
Find out more
All topic texts, Call documentation and details of how to apply can be found on the IMI website – www.imi.europa.eu
Webinars
Registration is open for the webinars on IMI2 – Call 13, which run until 15 December. We are running webinars on all Call topics, as well as a webinar on IMI’s rules and procedures. In addition, this time we will have a dedicated webinar for small and medium-sized enterprises (SMEs).
